Utility of Imaging of Nigrosome‐1 on 3T MRI and Its Comparison with 18F‐DOPA PET in the Diagnosis of Idiopathic Parkinson Disease and Atypical Parkinsonism
Authors:
- 14 September 2020
- journal article
- research article
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (2) , 224-230
Abstract
Background: Loss of nigrosome‐1 on 3T and 7T magnetic resonance imaging (MRI) is a recently explored imaging biomarker in the diagnosis of neurodegenerative parkinsonism.Objectives: This study was undertaken to evaluate the utility of imaging of nigrosome in the diagnosis of neurodegenerative parkinsonism on 3T MRI.Methods: An institution‐based prospective case–control study was conducted at a tertiary care center in North India. 3T venous blood oxygen level‐dependent (VenoBOLD) and high‐resolution susceptibility‐weighted imaging (SWI) imaging sequences in MRI were performed in 100 patients with parkinsonism (56 with idiopathic Parkinson's disease [IPD], 30 with young onset Parkinson's disease [YOPD], 12 with progressive supranuclear palsy, and 2 patients with multiple system atrophy) and 15 controls. Grading of nigrosome was done in both the sequences. Each patient underwent 18F‐DOPA positron emission tomography (PET), detailed neurological examination including Hoen and Yahr (H&Y) staging and Movement Disorder Society‐Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) scoring.Results: The diagnostic sensitivity and specificity of the detection of loss of nigrosome‐1 on VenoBOLD and SWI sequence at 3T MR imaging were 90% and 66.7% and 94% and 80%, respectively. A weak negative correlation was found between the grading of the nigrosome and clinical parameters (H&Y and UPDRS III). There was no correlation between the side of nigrosome loss and clinical asymmetry. However, nigrosome imaging was not able to differentiate between Parkinson's disease and atypical parkinsonism.Conclusions: The loss of nigrosome‐1 on 3T MRI on SWI and VenoBOLD sequences may serve as a potential imaging marker in the diagnosis of degenerative parkinsonian syndromes. However, it cannot differentiate between idiopathic Parkinson's disease and atypical parkinsonian syndromes.Keywords
This publication has 30 references indexed in Scilit:
- Visualization of nigrosome 1 and its loss in PDNeurology, 2013
- Seven‐tesla magnetic resonance images of the substantia nigra in Parkinson diseaseAnnals of Neurology, 2011
- Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological studyMovement Disorders, 2010
- The role of DAT-SPECT in movement disordersJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controlsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosisMovement Disorders, 2004
- The substantia nigra of the human brainBrain, 1999
- The substantia nigra of the human brainBrain, 1999
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)Neurology, 1996
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992